¼¼°èÀÇ ·çÀ̼Òü Ä¡¸Å Ä¡·á ½ÃÀå º¸°í¼­(2025³â)
Lewy Body Dementia Treatment Global Market Report 2025
»óǰÄÚµå : 1821683
¸®¼­Ä¡»ç : The Business Research Company
¹ßÇàÀÏ : On Demand Report
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 250 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,490 £Ü 6,457,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,490 £Ü 9,334,000
PDF (Site License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,490 £Ü 12,211,000
PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
¤± º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼Û±âÀÏÀº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

·çÀ̼Òü Ä¡¸Å Ä¡·á ½ÃÀå ±Ô¸ð´Â ÇâÈÄ ¼ö³â°£ °­·ÂÇÑ ¼ºÀåÀÌ ¿¹»óµË´Ï´Ù. 2029³â ¿¬Æò±Õ ¼ºÀå·ü(CAGR)Àº 6.9%¸¦ ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹ÃøµÇ°í 61¾ï 2,000¸¸ ´Þ·¯·Î ¼ºÀåÇÒ Àü¸ÁÀÔ´Ï´Ù. ¿¹Ãø ±â°£ µ¿¾ÈÀÇ ¼ºÀåÀº ½Å°æÇÐ ºÐ¾ßÀÇ ¹ßÀü, ÁýÁßÀûÀÎ ¿¬±¸ °èȹ, Á¤¹Ð ÀÇÇÐ ¹× ¹ÙÀÌ¿À¸¶Ä¿, Çù·ÂÀû ÀÇ·á ¸ðµ¨, ¿ø°ÝÀÇ·á È®´ë µî¿¡ ±âÀÎÇÒ ¼ö ÀÖ½À´Ï´Ù. ¿¹Ãø ±â°£ÀÇ ÁÖ¿ä µ¿Çâ¿¡´Â °¡Á· ¹× °£º´ÀÎ Áö¿ø, ÅëÇÕ Ä¡·á ¸ðµ¨, ¸ÂÃãÇü Ä¡·á Á¢±Ù¹ý, ºñ¾à¹°Àû ÁßÀç, µðÁöÅÐ Çコ ¼Ö·ç¼Ç µîÀÌ Æ÷ÇԵ˴ϴÙ.

ÇâÈÄ 5³â°£ 6.9% ¼ºÀåÀ̶ó´Â ¿¹ÃøÄ¡´Â ÀÌÀü Àü¸Á ´ëºñ 0.1% ¼ÒÆø Ç϶ôÇÑ ¼öÄ¡ÀÔ´Ï´Ù. ÀÌ Ç϶ôÀº ÁÖ·Î ¹Ì±¹°ú Ÿ±¹ °£ °ü¼¼ ¿µÇâ¿¡ ±âÀÎÇÕ´Ï´Ù. °ü¼¼ ÀλóÀ¸·Î µ§¸¶Å©¿Í ½ºÀ§½º¿¡¼­ Á¦Á¶µÈ Äݸ°¿¡½ºÅ×¶óÁ¦ ¾ïÁ¦Á¦ ¹× Ç×Á¤½Åº´ ¾àǰ °¡°ÝÀÌ ÃËÁøµÇ¾î ¹Ì±¹ ȯÀÚµéÀÇ ºÎ´ãÀÌ °¡ÁßµÉ Àü¸ÁÀÔ´Ï´Ù. ÀÌ´Â º¹ÀâÇÑ Ä¡¸Å Ä¡·á °ü¸®¿¡ µû¸¥ º»ÀÎ ºÎ´ã ºñ¿ëÀ» ¾ÇÈ­½Ãų °ÍÀÔ´Ï´Ù. ¶ÇÇÑ »óÈ£ °ü¼¼ ºÎ°ú¿Í ¹«¿ª ±äÀå ¹× Á¦ÇÑ °­È­·Î ÀÎÇÑ Àü ¼¼°è °æÁ¦ ¹× ¹«¿ª¿¡ ´ëÇÑ ºÎÁ¤Àû ¿µÇâÀ¸·Î ±× ÆÄ±Þ È¿°ú´Â ´õ¿í ±¤¹üÀ§ÇØÁú °ÍÀÔ´Ï´Ù.

³ë·É Àα¸ Áõ°¡°¡ ·çÀ̼Òü Ä¡¸Å Ä¡·á ½ÃÀå ¼ºÀåÀ» °ßÀÎÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. Àα¸ °í·ÉÈ­´Â »çȸ ³» ³ëÀÎ Àα¸ ºñÀ²ÀÌ Áõ°¡ÇÏ´Â Àα¸ÇÐÀû º¯È­¸¦ ÀǹÌÇÕ´Ï´Ù. ·çÀ̼Òü Ä¡¸Å Ä¡·á´Â ÀÌ ÁøÇ༺ ½Å°æÅðÇ༺ ÁúȯÀ¸·Î °íÅë¹Þ´Â °í·É Àα¸ÀÇ Áõ»ó °ü¸®, ÀÎÁö ±â´É Çâ»ó½Ã۸ç, »îÀÇ ÁúÀ» °³¼±ÇÏ´Â µ¥ ÇÙ½ÉÀûÀÎ ¿ªÇÒÀ» ÇÕ´Ï´Ù. 2022³â 1¿ù ¹Ì±¹ ½ÉÀåÇùȸ(American Heart Association Inc.)°¡ ¹ßÇ¥ÇÑ º¸°í¼­¿¡ µû¸£¸é 2060³â±îÁö ¹Ì±¹¿¡¼­ ³úÀåÇØ°¡ 930¸¸¸íÀ¸·Î Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ°í ÀÖ½À´Ï´Ù. ÇöÀç ³úÀåÇØÀÇ À¯º´·üÀº ¼¼°èÀûÀ¸·Î »ó½Â¼¼¿¡ ÀÖÀ¸¸ç, ¼¼°è 6¸í Áß 1¸íÀÌ º´À» ¾Î°í ÀÖÀ¸¸ç, 2021³â¿¡ 10¾ï¸íÀÌ ³úÀåÇØ¿¡ °É¸° °ÍÀ¸·Î ÃßÁ¤µÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ³ú °ü·Ã ÁúȯÀÇ ±ÞÁõÀº ·çÀ̼Òü Ä¡¸Å Ä¡·á ½ÃÀåÀÇ Áß¿äÇÑ ÃËÁø¿äÀÎÀÌ µÇ°í ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå ½ÃÀå Æ¯Â¡

Á¦3Àå ½ÃÀå µ¿Çâ°ú Àü·«

Á¦4Àå ½ÃÀå : ±Ý¸®, ÀÎÇ÷¹À̼Ç, ÁöÁ¤ÇÐ, ¹«¿ªÀüÀï°ú °ü¼¼, ±×¸®°í Äڷγª ¹× ȸº¹ÀÌ ½ÃÀå¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» Æ÷ÇÔÇÑ °Å½Ã°æÁ¦ ½Ã³ª¸®¿À

Á¦5Àå ¼¼°èÀÇ ¼ºÀå ºÐ¼®°ú Àü·« ºÐ¼® ÇÁ·¹ÀÓ¿öÅ©

Á¦6Àå ½ÃÀå ¼¼ºÐÈ­

Á¦7Àå Áö¿ªº° ¹× ±¹°¡º° ºÐ¼®

Á¦8Àå ¾Æ½Ã¾ÆÅÂÆò¾ç ½ÃÀå

Á¦9Àå Áß±¹ ½ÃÀå

Á¦10Àå Àεµ ½ÃÀå

Á¦11Àå ÀϺ» ½ÃÀå

Á¦12Àå È£ÁÖ ½ÃÀå

Á¦13Àå Àεµ³×½Ã¾Æ ½ÃÀå

Á¦14Àå Çѱ¹ ½ÃÀå

Á¦15Àå ¼­À¯·´ ½ÃÀå

Á¦16Àå ¿µ±¹ ½ÃÀå

Á¦17Àå µ¶ÀÏ ½ÃÀå

Á¦18Àå ÇÁ¶û½º ½ÃÀå

Á¦19Àå ÀÌÅ»¸®¾Æ ½ÃÀå

Á¦20Àå ½ºÆäÀÎ ½ÃÀå

Á¦21Àå µ¿À¯·´ ½ÃÀå

Á¦22Àå ·¯½Ã¾Æ ½ÃÀå

Á¦23Àå ºÏ¹Ì ½ÃÀå

Á¦24Àå ¹Ì±¹ ½ÃÀå

Á¦25Àå ij³ª´Ù ½ÃÀå

Á¦26Àå ³²¹Ì ½ÃÀå

Á¦27Àå ºê¶óÁú ½ÃÀå

Á¦28Àå Áßµ¿ ½ÃÀå

Á¦29Àå ¾ÆÇÁ¸®Ä« ½ÃÀå

Á¦30Àå °æÀï ±¸µµ¿Í ±â¾÷ ÇÁ·ÎÆÄÀÏ

Á¦31Àå ±âŸ ÁÖ¿ä ±â¾÷ ¹× Çõ½Å ±â¾÷

Á¦32Àå ¼¼°è ½ÃÀå °æÀï º¥Ä¡¸¶Å·°ú ´ë½Ãº¸µå

Á¦33Àå ÁÖ¿ä ÀμöÇÕº´(M&A)

Á¦34Àå ÃÖ±Ù ½ÃÀå µ¿Çâ

Á¦35Àå ½ÃÀåÀÇ ÀáÀç·ÂÀÌ ³ôÀº ±¹°¡, ºÎ¹®, Àü·«

Á¦36Àå ºÎ·Ï

HBR
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Lewy body dementia treatment encompasses both medications and nonmedical therapies aimed at managing symptoms and improving the overall well-being of individuals affected by the condition. Nonmedical therapies include physical, occupational, and speech therapies, while medications are used to alleviate symptoms such as hallucinations, confusion, drowsiness, movement problems, and disturbed sleep.

The main drug types in the Lewy body dementia treatment market include antidepressants, antipsychotic drugs, benzodiazepines, carbidopa-levodopa, cholinesterase inhibitors, and modafinil. Antidepressants are medications prescribed to treat depression and various related conditions, such as anxiety disorders, obsessive-compulsive disorder (OCD), chronic pain, eating disorders, and post-traumatic stress disorder (PTSD). They work by increasing the levels of certain chemicals in the brain to improve mood. Distribution channels for these treatments include hospitals pharmacies, retail pharmacies, online pharmacies, and others. These treatments are commonly used for conditions such as Alzheimer's disease, dementia, and Parkinson's disease.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The lewy body dementia treatment market research report is one of a series of new reports from The Business Research Company that provides lewy body dementia treatment market statistics, including lewy body dementia treatment industry global market size, regional shares, competitors with a lewy body dementia treatment market share, detailed lewy body dementia treatment market segments, market trends and opportunities, and any further data you may need to thrive in the lewy body dementia treatment industry. This lewy body dementia treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The lewy body dementia treatment market size has grown strongly in recent years. It will grow from $4.43 billion in 2024 to $4.69 billion in 2025 at a compound annual growth rate (CAGR) of 5.8%. The growth in the historic period can be attributed to supportive care and family education, regulatory approvals and guideline, multidisciplinary care approaches, psychosocial and behavioral interventions, multidisciplinary care approaches.

The lewy body dementia treatment market size is expected to see strong growth in the next few years. It will grow to $6.12 billion in 2029 at a compound annual growth rate (CAGR) of 6.9%. The growth in the forecast period can be attributed to advancements in neurology, focused research initiatives, precision medicine and biomarkers, collaborative healthcare models, telemedicine expansion. Major trends in the forecast period include family and caregiver support, integrated care models, personalized treatment approaches, non-pharmacological interventions, digital health solutions.

The forecast of 6.9% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff escalations are likely to burden U.S. patients by driving up the cost of cholinesterase inhibitors and antipsychotic medications manufactured in Denmark and Switzerland, exacerbating out-of-pocket expenses for complex dementia care management. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The lewy body dementia treatment market is anticipated to witness growth due to the increasing prevalence of brain-related disorders. Brain disorders encompass conditions that impact brain function, ranging from mild to severe impairment depending on the extent of brain damage. Treatments for lewy body dementia aim to address symptoms such as hallucinations, confusion, and drowsiness by enhancing brain chemicals to improve alertness and cognition. A report shared by the American Heart Association Inc. in January 2022 indicated a projected increase in brain disorders to 9.3 million in the US by 2060. Currently, the prevalence of brain disorders is on the rise globally, affecting one in every six people worldwide, with an estimated 1 billion individuals suffering from brain disorders by 2021. This surge in brain-related disorders is a significant driver for the lewy body dementia treatment market.

The growth of the Lewy body dementia treatment market is expected to be propelled by the rising aging population. An aging population signifies a demographic shift characterized by an increasing proportion of elderly individuals within society. Lewy body dementia treatments play a crucial role in managing symptoms, enhancing cognitive function, and improving the quality of life for the aging population affected by this progressive neurodegenerative disorder. According to the World Health Organization's projections in October 2022, by 2030, one out of every six individuals globally will be 60 years old or older. The proportion of the population aged 60 and over is expected to rise from 1 billion in 2020 to 1.4 billion during this period. Moreover, the global population of individuals aged 60 and older is anticipated to double by 2050, reaching 2.1 billion. Consequently, the rising aging population is a significant factor driving the Lewy body dementia treatment market.

Innovation emerges as a key trend in the lewy body dementia treatment market, with major companies focusing on developing innovative solutions to strengthen their market positions. Biogen Inc., a multinational biotechnology company, introduced lecanemab in January 2023. This humanized monoclonal antibody is designed to treat Alzheimer's disease, which is a component of Lewy body dementia. Lecanemab stands out by reducing brain amyloid levels, addressing amyloid plaques believed to contribute to cognitive impairment and dementia in Alzheimer's disease.

Major companies in the lewy body dementia treatment market are also concentrating on providing revolutionary transdermal systems that leverage innovative technology, such as CORPLEX technology for Alzheimer's dementia treatment. Corium, a biopharmaceutical leader in CNS therapies, launched ADLARITY in September 2022. This once-weekly transdermal system delivers donepezil for Alzheimer's patients, addressing the disease component in Lewy body dementia. Utilizing CORPLEX technology, it ensures sustained drug release for enhanced efficacy and reduced gastrointestinal side effects.

In October 2022, Pfizer Inc., a multinational pharmaceutical and biotechnology corporation, acquired Biohaven Pharmaceuticals Inc. for $11.6 billion. This strategic acquisition aims to enhance Pfizer's potential to offer new treatment options globally. Biohaven Pharmaceuticals Inc. is a pharmaceutical company focused on developing drugs for the treatment of Parkinson's disease, which is related to Lewy body dementia.

Major companies operating in the lewy body dementia treatment market include Mallinckrodt Pharmaceuticals Co., BioArctic AB, Sumitomo Pharma Co. Ltd., Jazz Pharmaceuticals Inc., Allergan plc, Novartis International AG, Pfizer Inc., Bayer AG, Boehringer Ingelheim International GmbH., Merck & Co. Inc., Biogen Inc., Biohaven Pharmaceutical Holding Company Ltd., Bristol Myers Squibb Company, Calliditas Therapeutics AB, Chiesi USA Inc., GlaxoSmithKline plc, Eisai Co. Ltd., Bausch Health Companies Inc., Hisamitsu Pharmaceutical Co. Inc., Lundbeck Inc.

North America was the largest region in the Lewy body dementia treatment market in 2024. The regions covered in the lewy body dementia treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the lewy body dementia treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The lewy body dementia treatment market consists of revenues earned by entities by providing speech and language therapy, physiotherapy, and psychological therapy services. The market value includes the value of related goods sold by the service provider or included within the service offering. The lewy body dementia treatment market also includes sales of rivastigmine, donepezil, and galantamine products, which are used in providing lewy body dementia treatment services. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Lewy Body Dementia Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on lewy body dementia treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for lewy body dementia treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The lewy body dementia treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Scope

Table of Contents

1. Executive Summary

2. Lewy Body Dementia Treatment Market Characteristics

3. Lewy Body Dementia Treatment Market Trends And Strategies

4. Lewy Body Dementia Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Lewy Body Dementia Treatment Growth Analysis And Strategic Analysis Framework

6. Lewy Body Dementia Treatment Market Segmentation

7. Lewy Body Dementia Treatment Market Regional And Country Analysis

8. Asia-Pacific Lewy Body Dementia Treatment Market

9. China Lewy Body Dementia Treatment Market

10. India Lewy Body Dementia Treatment Market

11. Japan Lewy Body Dementia Treatment Market

12. Australia Lewy Body Dementia Treatment Market

13. Indonesia Lewy Body Dementia Treatment Market

14. South Korea Lewy Body Dementia Treatment Market

15. Western Europe Lewy Body Dementia Treatment Market

16. UK Lewy Body Dementia Treatment Market

17. Germany Lewy Body Dementia Treatment Market

18. France Lewy Body Dementia Treatment Market

19. Italy Lewy Body Dementia Treatment Market

20. Spain Lewy Body Dementia Treatment Market

21. Eastern Europe Lewy Body Dementia Treatment Market

22. Russia Lewy Body Dementia Treatment Market

23. North America Lewy Body Dementia Treatment Market

24. USA Lewy Body Dementia Treatment Market

25. Canada Lewy Body Dementia Treatment Market

26. South America Lewy Body Dementia Treatment Market

27. Brazil Lewy Body Dementia Treatment Market

28. Middle East Lewy Body Dementia Treatment Market

29. Africa Lewy Body Dementia Treatment Market

30. Lewy Body Dementia Treatment Market Competitive Landscape And Company Profiles

31. Lewy Body Dementia Treatment Market Other Major And Innovative Companies

32. Global Lewy Body Dementia Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Lewy Body Dementia Treatment Market

34. Recent Developments In The Lewy Body Dementia Treatment Market

35. Lewy Body Dementia Treatment Market High Potential Countries, Segments and Strategies

36. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â